Apoptotic cells therapy for the prevention of cytokine release syndrome (CRS) in CAR T-cell therapy

      Allocetra™ (Enlivex Therapeutics Ltd.) is a cell-based therapy composed of donor mononuclear-enriched leukocytes, containing early apoptotic cells with no necrotic cells. It was shown as safe and potentially efficacious for the prevention of aGVHD in patients with hematologic malignancies (Mevorach et al. BBMT 2014). Chimeric antigen receptor (CAR)-modified T cells with specificity against CD19 have shown promise in highly refractory hematologic malignancies, albeit with significant toxicity. 30% of patients with acute lymphoblastic leukemia develop severe forms of CRS and possibly related neurotoxicity. CRS resembles macrophage-activating syndrome and hemophagocytosis in response to CAR T-secreting IFN-g and possibly added cytokines. We tested the effects of early apoptotic cells on CRS and CAR T cell cytotoxicity.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect